Results 261 to 270 of about 53,288 (296)

Hepatic Safety of Itraconazole [PDF]

Journal of Cutaneous Medicine and Surgery, 2002
Background: As the use of the newer oral antifungal agents for the treatment of superficial fungal infections becomes more widespread, the issue of safety surrounding their use is becoming an increasingly important consideration. Itraconazole is effective and well tolerated, with most side effects being minor and reversible.
James Q. Del Rosso, Elisabeth Chwetzoff, Aditya K. Gupta, Robert Baran   +3 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Itraconazole

Expert Opinion on Pharmacotherapy, 2000
Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial fungal infections including ...
G E, Piérard, J E, Arrese, C, Piérard-Franchimont   +2 more
openaire   +2 more sources

Pharmacology of Itraconazole

Drugs, 2001
Itraconazole is a triazole antifungal agent that has a broad spectrum of activity and is well tolerated. Itraconazole is highly efficacious, particularly because its main metabolite, hydroxy-itraconazole, also has considerable antifungal activity. The original capsule formulation of itraconazole may lead to variability in absorption and the plasma ...
Karel De Beule, Jef van Gestel
openaire   +3 more sources

Intravenous Itraconazole

Annals of Pharmacotherapy, 2001
OBJECTIVE: To review the pharmacology, mycology, chemistry, pharmacokinetics, efficacy, safety, tolerability, dosage, administration, and economic issues of intravenous itraconazole. DATA SOURCES: A MEDLINE search from 1978 to June 2000 of the English-language literature and an extensive review of meeting abstracts was conducted.
D, Slain, P D, Rogers, J D, Cleary, S W, Chapman   +3 more
openaire   +2 more sources

Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole

Clinica Chimica Acta, 2013
The pharmacokinetic variability of hydroxy-itraconazole (OH-ITZ), an active metabolite of itraconazole (ITZ), is not fully known.Oral solution of ITZ was administered in 46 immunocompromised patients as a single 200 mg dose for at least 12 days. The plasma concentrations of ITZ, active OH-ITZ, and keto-itraconazole (keto-ITZ), an inactive metabolite ...
Takahiro Yamada, Junichi Kawakami, Yasuaki Mino, Tatsuya Yagi, Takayuki Watanabe, Takayuki Watanabe, Hiroshi Yamada, Takafumi Naito   +7 more
openaire   +3 more sources

Treatment of paracoccidioidomycosis with itraconazole

Medical Mycology, 1990
Forty-seven patients with active paracoccidioidomycosis were treated with itraconazole. The majority of the patients (45) had the chronic adult form of the disease while the remaining exhibited the juvenile form. All of the patients received itraconazole, 100 mg day-1, with the exception of two for whom the clinical condition necessitated a larger dose.
M. I. Múnera, P. Restrepo, Iván Gómez, M. S. Naranjo, M. Trujillo, Angela Restrepo   +5 more
openaire   +2 more sources

Treatment of Aspergillosis with Itraconazole

Annals of Pharmacotherapy, 1993
OBJECTIVE: To review the role of itraconazole as oral therapy for the major infections caused by Aspergillus spp.: allergic bronchopulmonary aspergillosis, aspergilloma, and invasive aspergillosis. DATA SOURCES: A MEDLINE search of articles published in the English language between 1986 and 1993 was used to identify relevant citations, including review
Timothy S. Jennings, Thomas C. Hardin
openaire   +3 more sources

Itraconazole in Cyclodextrin Solution [PDF]

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1999
Itraconazole, a water‐insoluble oral triazole antifungal, has been formulated in cyclodextrin as a solution. Cyclodextrin is a ring of glucose molecules that can accept a lipophilic guest molecule within the ring. This enables solubilization and delivery to the lipid interface of the gut lumen, resulting in absorption of the guest molecule without ...
openaire   +2 more sources

Itraconazole for the treatment of onychomycosis

International Journal of Dermatology, 1998
Background The broad spectrum of activity of itraconazole in vitro manifests itself clinically with the drug being effective for the treatment of onychomycosis caused by dermatophytes, Candida and some non‐dermatophyte molds. The pharmacokinetics of itraconazole in the nail results in drug remaining at therapeutic levels for 6–9 months after ...
Ralph Daniel, Josette André, Piet De Doncker, Aditya K. Gupta, Richard K. Scher, Robert Baran, Eckart Haneke   +6 more
openaire   +3 more sources

Treatment of Mycoses with Itraconazole

Annals of the New York Academy of Sciences, 1988
The efficacy of itraconazole, a new oral triazole, was evaluated at doses of 50-400 mg/day in 64 courses: 39 with coccidioidomycosis, and 25 with other mycoses. Among patients with coccidioidomycosis, 21 had pulmonary disease; 10, bone and joint; 8, lymphatic; 6, skin and soft tissue; 3, meningeal; and 1, urogenital.
Paul L. Williams, David A. Stevens, Richard M. Tucker, Eduardo G. Arathoon   +3 more
openaire   +3 more sources